Chargement en cours...
Exposure‐response relationship of certolizumab pegol induction and maintenance therapy in patients with Crohn's disease
BACKGROUND: Therapeutic drug monitoring may optimize therapy for Crohn's disease (CD). AIM: To use a population pharmacokinetic model that accounts for the time‐varying nature of covariates to simulate certolizumab pegol (CZP) concentrations to evaluate the exposure‐response relationship for CZ...
Enregistré dans:
| Publié dans: | Aliment Pharmacol Ther |
|---|---|
| Auteurs principaux: | , , , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5765392/ https://ncbi.nlm.nih.gov/pubmed/29159893 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/apt.14421 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|